DFMO-sulindac combination reduces incidence of advanced adenomas by 92%

    loading  Checking for direct PDF access through Ovid

Abstract

▪ A Phase III trial of patients with a history of adenomas demonstrated that a low-dose combination of difluormethylornithine (DFMO) and sulindac reduced the incidence of any adenoma by 70% and of advanced adenomas by 92%. Experts described the results as ‘stunning’.

Related Topics

    loading  Loading Related Articles